The University of Tokyo

Hanavax Inc.

Nippondenso Co., Ltd.

The Uab Research Foundation

Tokyo Medical and Dental University

Jasco Corporation

Intellectual Property Strategy Network, Inc.

Yoshikazu Yuki

Hiroshi Kiyono

Kazunari Akiyoshi

Rika Nakahashi

Mitsuo Watanabe

David E Briles

Masashi Nishimoto

Takehito Mizutani

Kiyoharu Kutsuna

Akio Wada

Kristopher Genschmer

Shiho Kurokawa

Shinichi Sawada

Reshmi Mukerji

Kazuhisa Hayashi

Kazunori Ebisawa

Tomonori Nochi

Robert Kneller

The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains stability as a molecule even around neutral pH range. Specifically, the present invention relates to a protein of the following (a) or (b):

Pneumococcal surface proteins

The present embodiments provide compositions and methods related to novel recombinant protein immunogens, comprising specific portions of alpha helical domains (aHD) and proline rich regions (PRD) of pneumococcal surface protein A (PspA), which portions are linked to provide aHD-PRD constructs. The aHD and PRD proteins constituting the aHD-PRD constructs are selected to maximize cross-reactivity and provide protection against a broad spectrum of pneumococcal serotypes. Immunogenic compositions, including vaccines, comprising at least one aHD PRD construct may also include a non-linked aHD portion. Also provided are recombinant nucleic acid molecules that encode aHD-PRD constructs, vectors and recombinant host cells containing such molecules, aHD-PRD expression products, use of such nucleic acid molecules to express aHD-PRD constructs by recombinant techniques, and use of the expression products to elicit an immune or protective response against pneumococcal disease in a suitable host.

Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein A

The present invention provides a nanogel nasal vaccine that induces cell-mediated immunity. The present invention relates to a vaccine preparation comprising a complex of a nanogel, a vaccine antigen, and an adjuvant, wherein the vaccine preparation can efficiently induce the cell-mediated immunity, and can also induce a systemic and mucosal immune response.

Intranasal vaccine that induces cellular immunity

An antibody is provided that inhibits infection of cells with a norovirus. The antibody is a nanoantibody comprising a polypeptide described in (a), (b), or (c), and inhibiting infection of intestinal cells with HuNoV GII.4: (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; (b) a polypeptide consisting of an amino acid sequence comprising a substitution, deletion, insertion and/or addition of one or several amino acids with respect to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13; and (c) a polypeptide consisting of an amino acid sequence having a sequence identity of 80% or more to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 13.

Norovirus antibody

The present invention provides a nasal vaccine for, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.

[object Object]

A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route.

Mucosal vaccine using cationic nanogel

A concentration correcting apparatus comprising a correction coefficient calculating means and a correcting means is shown and described. The correction coefficient calculating means calculates a correction coefficient for correcting the concentration of the material when the actual density of the medium at the measurement of the material is calculated in terms of the density of the medium under the reference temperature and pressure, from the results of the temperature measuring means and the pressure measuring means. The correcting means corrects the results of the material measuring means to a concentration under the reference temperature and pressure on the basis of the correction coefficient. The measure value of the material in the medium under constant temperature and depressure is virtually calculated by correcting the measured value by using the correction coefficient while calculating the volume of the medium which is regarded as a parameter of a temperature and a pressure in terms of a volume under the constant temperature and pressure. It is therefore possible to calculate the concentration per unit weight under constant conditions even if the temperature and the pressure are varied at the time of measurement.

Method and apparatus for correcting concentration

Growing community of inventors

Tokyo, Japan

Yoshikazu Yuki